UMF Corporation has partnered with Medentech to bring Klorese®, a private-labeled version of Klorkleen2 disinfectant, to the U.S. market, according to a recent news release.
Registered by the EPA (#71847-7-94101), Klorese is included on the EPA List N for use against SARS-CoV-2, the virus that causes COVID-19, and List K for use against Clostridioides difficile (C. diff). Klorese is a hospital-grade disinfectant that produces hypochlorous acid (HOCL), the same antimicrobial chemical produced by the human body to fight infection. The disinfectant has broad-spectrum effectiveness against human coronavirus, C. diff, Candida Auris, MRSA and additional bacteria, fungi, spores, viruses and mycobacteria.
According to the release, Klorese is the only disinfectant with an EPA registered claim against biofilm, which protects bacteria from a wide variety of disinfection practices. Pervasive throughout most facilities, biofilm formation is associated with 65% of microbial infections and 80% of chronic infections, according to the National Institutes of Health. In preparation for EPA registration, Klorese was also tested successfully against human norovirus.
“With infection prevention more in the spotlight than ever as the world battles COVID-19, we are privileged to partner with Medentech to introduce Klorese to the U.S. market,” said UMF CEO George Clarke. “Klorese is a powerful yet user and surface friendly disinfectant, utilizing the very same active ingredient, HOCL, as our immune system produces to fight microbes – it is indeed effectively human. The combination of Klorese and UMF’s PerfectCLEAN high-performance products for commercial cleaning and disinfection enables safe removal and elimination of every contaminant from a surface within minutes in any environment.”
Klorese is available in a sustainable effervescent tablet form. The minimal packaging it requires is recyclable. With Klorese, hospitals and healthcare suppliers can maintain significant inventory levels in a fraction of the space required for most disinfectants; reduce shipping costs; and eliminate the need for dispensing systems and their associated maintenance costs. Klorese allows hospitals and healthcare suppliers to maintain sufficient levels of product in preparation for future events, which is particularly important given the shortages faced due to COVID-19.
“Medentech’s primary mission is to reduce surface contamination by developing, manufacturing and marketing cost-effective disinfection solutions,” said Michael Gately, managing director, Medentech. “We partnered with UMF Corporation to broaden the reach of our solutions, which are clinically formulated by scientists at Medentech’s on-site R&D facility. Klorese disinfection tablets offer protection against multitudes of microorganisms, as well as the biofilms that offer such germs protection and abound in critical care environments.”
